New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:08 EDTIMMUImmunomedics announces presentation of epratuzumab data
Immunomedics announced that scientific data on epratuzumab, an investigational therapy for the treatment of systemic lupus erythematosus, also known as lupus, will be presented at the European League Against Rheumatism 2014 Annual Congress to be held in Paris, France. Epratuzumab is an investigational medicine in Phase III clinical development for the treatment of SLE. Epratuzumab is a monoclonal antibody that targets CD22. Epratuzumab is not approved for the treatment of SLE by any regulatory authority worldwide. Immunomedics has granted UCB exclusive worldwide rights to develop, market, and sell epratuzumab for all autoimmune disease indications.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 19, 2015
14:34 EDTIMMUImmunomedics presents updated results with sacituzumab govitecan in lung cancer
Immunomedics announced that 33% of patients with small cell lung cancer, SCLC, and 31% with non-small cell lung cancer, NSCLC, had their tumor reduced in size by 30% or more, after being treated with sacituzumab govitecan, the company's lead investigational antibody-drug conjugate, ADC. Including patients that reported stable disease as their best response, the ADC controls the progression of the cancer in 75% and 56% of NSCLC and SCLC patients, respectively. These patients had either failed to respond to their last lung cancer therapies or their cancer had returned or progressed. Dr. Francois Wilhelm, Chief Medical Officer, presented the updated results at the 15th Annual Targeted Therapies of Lung Cancer Meeting, an invitation-only meeting sponsored by The International Association for the Study of Lung Cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use